The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Mark A. Giembycz

Airways Inflammation Research Group

Departments of Physiology and Pharmacology

Institute of Infection

Immunity and Inflammation



Name/email consistency: high



  • Airways Inflammation Research Group, Departments of Physiology and Pharmacology, Institute of Infection, Immunity and Inflammation, Canada. 2005 - 2011


  1. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Giembycz, M.A., Newton, R. Handb. Exp. Pharmacol (2011) [Pubmed]
  2. An estimation of beta 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. Giembycz, M.A. Br. J. Pharmacol. (2009) [Pubmed]
  3. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Giembycz, M.A., Kaur, M., Leigh, R., Newton, R. Br. J. Pharmacol. (2008) [Pubmed]
  4. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Giembycz, M.A. Br. J. Pharmacol. (2008) [Pubmed]
  5. Beyond the dogma: novel beta2-adrenoceptor signalling in the airways. Giembycz, M.A., Newton, R. Eur. Respir. J. (2006) [Pubmed]
  6. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Giembycz, M.A. Br. J. Clin. Pharmacol (2006) [Pubmed]
  7. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?. Giembycz, M.A., Smith, S.J. Curr. Pharm. Des. (2006) [Pubmed]
  8. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Giembycz, M.A. Curr. Opin. Pharmacol (2005) [Pubmed]
  9. Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Giembycz, M.A. Proc. Am. Thorac. Soc (2005) [Pubmed]
WikiGenes - Universities